NewAmsterdam Pharma's COO Kling to resign, take CEO role elsewhere
Douglas Kling will step down as chief operating officer effective August 14, 2026, and is expected to advise on the company's obicetrapib trial work under a separate agreement.
NewAmsterdam Pharma Company N.V. disclosed in a Form 8-K dated July 16, 2026 that Douglas Kling notified the company he would resign as chief operating officer, effective August 14, 2026, to become chief executive officer of another clinical-stage biotech company.1
The company said it expects to enter into a separation agreement in connection with Kling's departure.1 It also said it expects to enter into an advisor agreement with Kling under which he would help with the transition and offer advice tied to the company's PREVAIL clinical trial of obicetrapib, along with other clinical programs, though the terms still need to be worked out by both sides.1
NewAmsterdam Pharma noted that the specific terms of any separation agreement and advisor agreement will be disclosed in a later amendment to this Form 8-K.1
The filing was signed on July 22, 2026 by Mike Marino, the company's Chief Legal Officer.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.